Mark A. Velleca

2023 - Black Diamond Therapeutics

In 2023, Mark A. Velleca earned a total compensation of $2.9M as President and Chief Executive Officer at Black Diamond Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$113,667
Option Awards$2,591,404
Salary$180,333
Other$63,950
Total$2,949,854

Velleca received $2.6M in option awards, accounting for 88% of the total pay in 2023.

Velleca also received $113.7K in non-equity incentive plan, $180.3K in salary and $64K in other compensation.

Rankings

In 2023, Mark A. Velleca's compensation ranked 311th out of 2,910 executives tracked by ExecPay. In other words, Velleca earned more than 89.3% of executives.

ClassificationRankingPercentile
All
311
out of 2,910
89th
Division
Manufacturing
172
out of 1,602
89th
Major group
Chemicals And Allied Products
116
out of 901
87th
Industry group
Drugs
113
out of 864
87th
Industry
Biological Products, Except Diagnostic Substances
39
out of 211
82nd
Source: SEC filing on April 24, 2024.

Velleca's colleagues

We found three more compensation records of executives who worked with Mark A. Velleca at Black Diamond Therapeutics in 2023.

2023

David Epstein

Black Diamond Therapeutics

Chief Executive Officer

2023

Fang Ni

Black Diamond Therapeutics

Chief Financial Officer

2023

Sergey Yurasov

Black Diamond Therapeutics

Chief Medical Officer

News

In-depth

You may also like